The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers
Head and neck cancer (HNC) is the sixth most common cancer type, accounting for approximately 277,597 deaths worldwide. Recently, the Food and Drug Administration (FDA) has approved immune checkpoint blockade (ICB) agents targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) as a...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-02-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223018930 |
| _version_ | 1797324394222059520 |
|---|---|
| author | Sarra Mestiri Dina Moustafa Abo El-Ella Queenie Fernandes Takwa Bedhiafi Salam Almoghrabi Shayista Akbar Varghese Inchakalody Laila Assami Shaheena Anwar Shahab Uddin Abdul Rehman Zar Gul Mariam Al-Muftah Maysaloun Merhi Afsheen Raza Said Dermime |
| author_facet | Sarra Mestiri Dina Moustafa Abo El-Ella Queenie Fernandes Takwa Bedhiafi Salam Almoghrabi Shayista Akbar Varghese Inchakalody Laila Assami Shaheena Anwar Shahab Uddin Abdul Rehman Zar Gul Mariam Al-Muftah Maysaloun Merhi Afsheen Raza Said Dermime |
| author_sort | Sarra Mestiri |
| collection | DOAJ |
| description | Head and neck cancer (HNC) is the sixth most common cancer type, accounting for approximately 277,597 deaths worldwide. Recently, the Food and Drug Administration (FDA) has approved immune checkpoint blockade (ICB) agents targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) as a treatment regimen for head and neck squamous cell carcinomas (HNSCC). Studies have reported the role of immune checkpoint inhibitors as targeted therapeutic regimens that unleash the immune response against HNSCC tumors. However, the overall response rates to immunotherapy vary between 14–32% in recurrent or metastatic HNSCC, with clinical response and treatment success being unpredictable. Keeping this perspective in mind, it is imperative to understand the role of T cells, natural killer cells, and antigen-presenting cells in modulating the immune response to immunotherapy. In lieu of this, these immune molecules could serve as prognostic and predictive biomarkers to facilitate longitudinal monitoring and understanding of treatment dynamics. These immune biomarkers could pave the path for personalized monitoring and management of HNSCC. In this review, we aim to provide updated immunological insight on the mechanism of action, expression, and the clinical application of immune cells' stimulatory and inhibitory molecules as prognostic and predictive biomarkers in HNC. The review is focused mainly on CD27 and CD137 (members of the TNF-receptor superfamily), natural killer group 2 member D (NKG2D), tumor necrosis factor receptor superfamily member 4 (TNFRSF4 or OX40), S100 proteins, PD-1, PD-L1, PD-L2, T cell immunoglobulin and mucin domain 3 (TIM-3), cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), indoleamine-pyrrole 2,3-dioxygenase (IDO), B and T lymphocyte attenuator (BTLA). It also highlights the importance of T, natural killer, and antigen-presenting cells as robust biomarker tools for understanding immune checkpoint inhibitor-based treatment dynamics. Though a comprehensive review, all aspects of the immune molecules could not be covered as they were beyond the scope of the review; Further review articles can cover other aspects to bridge the knowledge gap. |
| first_indexed | 2024-03-08T05:55:31Z |
| format | Article |
| id | doaj.art-4ae8e28a28d84f9b885eec20fdd9367f |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-08T05:55:31Z |
| publishDate | 2024-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-4ae8e28a28d84f9b885eec20fdd9367f2024-02-05T04:31:02ZengElsevierBiomedicine & Pharmacotherapy0753-33222024-02-01171116095The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancersSarra Mestiri0Dina Moustafa Abo El-Ella1Queenie Fernandes2Takwa Bedhiafi3Salam Almoghrabi4Shayista Akbar5Varghese Inchakalody6Laila Assami7Shaheena Anwar8Shahab Uddin9Abdul Rehman Zar Gul10Mariam Al-Muftah11Maysaloun Merhi12Afsheen Raza13Said Dermime14Translational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; College of Medicine, Qatar University, Doha, QatarTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarDepartment of Biosciences, Salim Habib University, Karachi, PakistanTranslational Research Institute and Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar; Laboratory Animal Research Center, Qatar University, Doha, QatarNational Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarTranslational Cancer and Immunity Centre, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha, Qatar; College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, QatarTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarDepartment of Biomedical Sciences, College of Health Science, Abu Dhabi University, Abu Dhabi, United Arab EmiratesTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar; Correspondence to: Senior Scientist/ Director of Translational Cancer Research Facility National Center for Cancer Care and Research Hamad Medical Corporation Adjunct Associate Professor College of Health and Life Sciences (CHLS) Hamad Bin Khalifa University Doha, Qatar.Head and neck cancer (HNC) is the sixth most common cancer type, accounting for approximately 277,597 deaths worldwide. Recently, the Food and Drug Administration (FDA) has approved immune checkpoint blockade (ICB) agents targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) as a treatment regimen for head and neck squamous cell carcinomas (HNSCC). Studies have reported the role of immune checkpoint inhibitors as targeted therapeutic regimens that unleash the immune response against HNSCC tumors. However, the overall response rates to immunotherapy vary between 14–32% in recurrent or metastatic HNSCC, with clinical response and treatment success being unpredictable. Keeping this perspective in mind, it is imperative to understand the role of T cells, natural killer cells, and antigen-presenting cells in modulating the immune response to immunotherapy. In lieu of this, these immune molecules could serve as prognostic and predictive biomarkers to facilitate longitudinal monitoring and understanding of treatment dynamics. These immune biomarkers could pave the path for personalized monitoring and management of HNSCC. In this review, we aim to provide updated immunological insight on the mechanism of action, expression, and the clinical application of immune cells' stimulatory and inhibitory molecules as prognostic and predictive biomarkers in HNC. The review is focused mainly on CD27 and CD137 (members of the TNF-receptor superfamily), natural killer group 2 member D (NKG2D), tumor necrosis factor receptor superfamily member 4 (TNFRSF4 or OX40), S100 proteins, PD-1, PD-L1, PD-L2, T cell immunoglobulin and mucin domain 3 (TIM-3), cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), indoleamine-pyrrole 2,3-dioxygenase (IDO), B and T lymphocyte attenuator (BTLA). It also highlights the importance of T, natural killer, and antigen-presenting cells as robust biomarker tools for understanding immune checkpoint inhibitor-based treatment dynamics. Though a comprehensive review, all aspects of the immune molecules could not be covered as they were beyond the scope of the review; Further review articles can cover other aspects to bridge the knowledge gap.http://www.sciencedirect.com/science/article/pii/S0753332223018930Head and neck cancerImmune checkpoint moleculesStimulatory and inhibitory biomarkersDiagnosisAnd prognosis biomarkers |
| spellingShingle | Sarra Mestiri Dina Moustafa Abo El-Ella Queenie Fernandes Takwa Bedhiafi Salam Almoghrabi Shayista Akbar Varghese Inchakalody Laila Assami Shaheena Anwar Shahab Uddin Abdul Rehman Zar Gul Mariam Al-Muftah Maysaloun Merhi Afsheen Raza Said Dermime The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers Biomedicine & Pharmacotherapy Head and neck cancer Immune checkpoint molecules Stimulatory and inhibitory biomarkers Diagnosis And prognosis biomarkers |
| title | The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers |
| title_full | The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers |
| title_fullStr | The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers |
| title_full_unstemmed | The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers |
| title_short | The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers |
| title_sort | dynamic role of immune checkpoint molecules in diagnosis prognosis and treatment of head and neck cancers |
| topic | Head and neck cancer Immune checkpoint molecules Stimulatory and inhibitory biomarkers Diagnosis And prognosis biomarkers |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223018930 |
| work_keys_str_mv | AT sarramestiri thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT dinamoustafaaboelella thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT queeniefernandes thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT takwabedhiafi thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT salamalmoghrabi thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT shayistaakbar thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT vargheseinchakalody thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT lailaassami thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT shaheenaanwar thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT shahabuddin thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT abdulrehmanzargul thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT mariamalmuftah thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT maysalounmerhi thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT afsheenraza thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT saiddermime thedynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT sarramestiri dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT dinamoustafaaboelella dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT queeniefernandes dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT takwabedhiafi dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT salamalmoghrabi dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT shayistaakbar dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT vargheseinchakalody dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT lailaassami dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT shaheenaanwar dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT shahabuddin dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT abdulrehmanzargul dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT mariamalmuftah dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT maysalounmerhi dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT afsheenraza dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers AT saiddermime dynamicroleofimmunecheckpointmoleculesindiagnosisprognosisandtreatmentofheadandneckcancers |